中药联合化疗治疗广泛期小细胞肺癌临床研究  被引量:7

Clinical research of traditional Chinese medicine combined with chemotherapy in treating extensive stage small cell lung cancer

在线阅读下载全文

作  者:冉文华[1] 魏章英[1] 孙支芳[2] 马维蓉[3] 罗晓红[4] 岳书华[2] 林建萍[5] 王国平[1] 

机构地区:[1]重庆三峡中心医院肿瘤科 [2]重庆三峡中心医院药剂科 [3]重庆三峡中心医院门诊部 [4]重庆三峡中心医院体检中心,重庆万州404000 [5]重庆三峡中心医院超声科

出  处:《川北医学院学报》2014年第5期470-473,共4页Journal of North Sichuan Medical College

基  金:重庆市卫生局科研项目资助(2012-2-176)

摘  要:目的:探讨中药喜丹汤联合化疗治疗广泛期小细胞肺癌能否提高疗效。方法:经病理明确诊断的未经手术治疗的120例广泛期小细胞肺癌患者,随机分为对照组与研究组各60例,对照组采用EP方案化疗治疗,研究组采用中药喜丹汤联合EP方案治疗。结果:研究组与对照组总有效率(CR+PR) 分别为75.0%(45/60)、56.7%(33/60),两组比较有统计学差异(P<0.05),中位生存时间及生存时间曲线:研究组10.9个月(10.5~11.2);对照组8.1个月(7.4~8.8),两组比较有显著的统计学意义(P<0.001);1年生存率研究组为53.3%(32/60),对照组为31.7%(19/60),两组比较差异有统计学意义(P<0.05);常见的毒副反应主要表现为血液学毒性及胃肠道反应,患者均可耐受。结论:中药联合化疗能提高广泛期小细胞肺癌的疗效,延长其生存期。Objective:To investigate the clinic effect of traditional Chinese medicine combined with chemotherapy in treating exten-sive stage small cell lung cancer( ES-SCLC) . Methods:120 cases of patients with ES-SCLC treated without surgery were divided ran-domly into the control group treated with EP regimen and the experimental group treated with traditional Chinese medicine ( XIDAN soup) combined with EP regimen,with sixty patients in each group. Results:In the study group the overall response rate( CR+PR) was 75. 0%,In the control group the overall response rate( CR+PR) was 56. 7%. There was statistical difference in the overall response rate between the two groups(P〈0. 05). The median survivals and time-survivor curve for the control group and study group were 8. 1 months and 10. 9 months respectively,which was statistically different between the two groups(P〈0. 05). 1 year survival rate for the control group and study group were 53. 3% and 31. 7%,respectively,which was statistically different between the two groups(P 〈0. 05). The major side effects were hematologic toxicities and gastrointestinal reactions,and the patients can tolerate it. Conclusion:The treatment of Chinese medicine combined with chemotherapy can improve the therapeutic efficacy and prolong survival period of ES-SCLC patients.

关 键 词:广泛期小细胞肺癌 化学治疗 中药治疗 中西医结合治疗 

分 类 号:R735.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象